Skip to content

Technical validation of quantitative methods for 3 'deoxy-3-[18F] fluorothymidine ([18F] FLT) PET in liver metastases of colorectal cancer patients

Technical validation of quantitative methods for 3 'deoxy-3-[18F] fluorothymidine ([18F] FLT) PET in liver metastases of colorectal cancer patients - FLT PET Liver

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41755
Enrollment
5
Registered
2014-05-23
Start date
2014-11-21
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastasis metastasis of gut cancer in the liver

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient age 18 years or older Histological diagnosis of mCRC (stage IV) without options for localregional treatment Presence of liver metastases on CT scan Presence of at least one liver metastases of >20mm in diameter on the CT scan Upper part of liver with left heart ventricle in field of view Able to remain supine for 90 minutes in the PET-CT scanner Ability to give study specific written informed consent

Exclusion criteria

Exclusion criteria: Pregnant or lactating patients (positive pregnancy test) Metal implants (eg pacemakers) Body weight > 100 kg Severe claustrophobia Receiving chemotherapy less than 2 months prior to the first PET scan, except in the case of progression under chemotherapy than a 2 week interval is required.

Design outcomes

Primary

MeasureTime frame
The proportion of number of concordant lesion observed with both [18F] FLTPET and CT scans on the total number of lesions observed with the CT scan (qualitative assessment).

Secondary

MeasureTime frame
1. Measurements per lesion from full kinetic filtering model 2. Measurements per lesion from simplified models 3.Test-retest reproducibility of each quantitative assessment of tumor [18F] FLT uptake 4. Correlation of full kinetic modeling with more simplified model per lesion

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)